Home Cart Sign in  
Chemical Structure| 80681-45-4 Chemical Structure| 80681-45-4

Structure of Prim-O-glucosylcimifugin
CAS No.: 80681-45-4

Chemical Structure| 80681-45-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Prim-O-glucosylcimifugin is a natural product isolated and purified from the root of Saposhnikovia divaricata (Turcz.) Schischk., which can inhibit the proliferation of SMC(smooth muscle cell) stimulated by TNF-alpha, increase the proportion of G0/G1 phase.

Synonyms: 1''-O-Glucosylcimifugin; Cimifugin beta-D-glucopyranoside; PGCN

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Prim-O-glucosylcimifugin

CAS No. :80681-45-4
Formula : C22H28O11
M.W : 468.45
SMILES Code : CC([C@@H]1CC2=C(OC)C(C(C=C(O3)CO[C@@]4([H])[C@H](O)[C@@H](O)[C@H](O)[C@H](O4)CO)=O)=C3C=C2O1)(O)C
Synonyms :
1''-O-Glucosylcimifugin; Cimifugin beta-D-glucopyranoside; PGCN
MDL No. :MFCD09037394
InChI Key :XIUVHOSBSDYXRG-UVTAEQIVSA-N
Pubchem ID :14034912

Safety of Prim-O-glucosylcimifugin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
B16-F10 cells 50 μM and 100 μM 48 hours To evaluate the effect of POG on apoptosis and proliferation of B16-F10 cells. The results showed that POG exhibited no cytotoxic effect on B16-F10 cells. PMC6714432
CD8 T-lymphocytes 50 μM and 100 μM 48 hours To evaluate the effect of POG on apoptosis and proliferation of CD8 T-lymphocytes. The results showed that POG exhibited no cytotoxic effect on CD8 T-lymphocytes and did not affect their proliferation. PMC6714432
PMN-MDSCs 50 μM and 100 μM 48 hours To evaluate the effect of POG on apoptosis and proliferation of PMN-MDSCs. The results showed that POG exhibited no cytotoxic effect on PMN-MDSCs but could specifically inhibit the proliferation of PMN-MDSCs. PMC6714432
Human tendon stem/progenitor cells (hTSPCs) 20 μmol·L−1 once every 2 days for 7 days POG treatment enhanced colony formation and proliferative capacity of hTSPCs and reduced senescence markers PMC10593834
Rat tendon stem/progenitor cells (rTSPCs) 20 μmol·L−1 long-term passage from P3 to P12 POG treatment significantly enhanced self-renewal and proliferative capacities of rTSPCs, reduced senescence markers, and restored tenogenic differentiation potential PMC10593834
RAW 264.7 mouse macrophage cells 12.5, 25, 50 μg/mL 1 hour To evaluate the inhibitory effect of Prim-O-glucosylcimifugin on LPS-induced cytokine production. Results showed that Prim-O-glucosylcimifugin significantly inhibited the production of TNF-α, IL-1β, and IL-6, and increased the level of IL-10. PMC7106058
RAW264.7 cells 12.5, 25, 50 μmol/mL 24 hours POG significantly suppressed the production of inflammatory factors (TNF-α, IL-1β, IL-6) in LPS-induced RAW264.7 cells and inhibited inflammatory responses by suppressing the phosphorylation of ERK1/2, AKT, JNK1/2, IκB-α, P38, and P65. PMC9158503
Human SGC7901 GC cell line 100 μM To evaluate the inhibitory effects of POG and its metabolite cimifugin on COX-2 expression, results showed that POG and cimifugin downregulated COX-2 expression PMC4930286
A549/DDP cells 0–10 μM 48 hours Decreased GST activity by ∼5%, decreased GSTPi1 expression by ∼18%, decreased GSTM1 expression by ∼50%, increased intracellular platinum accumulation by ∼30%, enhanced cell apoptosis by ∼10% PMC8202081
A549 cells 0–10 μM 48 hours Decreased GST activity by ∼10%, decreased GSTPi1 expression by ∼33%, decreased GSTM1 expression by ∼70%, increased intracellular platinum accumulation by ∼56%, enhanced cell apoptosis by ∼10% PMC8202081

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice B16-F10 melanoma model Intraperitoneal injection 100 mg/kg/day and 200 mg/kg/day Once daily for 14 days To evaluate the dose-dependent effect of POG on B16-F10 tumor growth. The results showed that POG significantly inhibited tumor growth in a dose-dependent manner, and 200 mg/kg had no significant effect on the body weight of mice. PMC6714432
Rats Partial transection tendon injury model in 18-month-old rats Oral 50 mg/kg body weight per day Once daily for 2 months Oral POG significantly improved tendon self-healing capacity in aged rats, reducing inflammation and senescence markers PMC10593834
BALB/c male mice LPS-induced acute lung injury model Intraperitoneal injection 2.5, 5, 10 mg/kg Single dose, lasting 7 hours To evaluate the protective effect of Prim-O-glucosylcimifugin on LPS-induced acute lung injury. Results showed that Prim-O-glucosylcimifugin significantly reduced inflammatory cell infiltration, edema, and MPO activity in lung tissues, and improved histopathological changes. PMC7106058
C57BL/6 mice DSS-induced ulcerative colitis model Intraperitoneal injection 2.5, 5, 10 mg/kg 7 consecutive days POG improved clinical scores, colonic length, and body weight in DSS-induced ulcerative colitis mice, repaired pathological damage to the intestinal mucosa, inhibited levels of inflammatory factors (IL-1β, TNF-α, IL-6), and repaired the intestinal immune barrier by upregulating the expression of tight junction proteins (Occludin, Claudin-3, ZO-1). Additionally, POG regulated the richness and structure of intestinal microbiota. PMC9158503
Wistar rats Formalin-induced tonic nociceptive response model and CFA-induced rat arthritis pain model Subcutaneous injection 1, 3, 10, 30 mg/kg Single dose or consecutive administration for 7 days To evaluate the anti-nociceptive effects of POG in inflammatory nociception, results showed that POG dose-dependently inhibited nociceptive responses without tolerance, reduced serum TNFα, IL-1β, and IL-6 levels, and decreased spinal PGE2 and COX-2 expression PMC4930286

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.67mL

2.13mL

1.07mL

21.35mL

4.27mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories